Scholar Rock Sees Phase III Path For SMA Drug

Apitegromab Being Studied As Monotherapy And In Combination

While the drug may be well-positioned for registrational development, some important caveats remain after mixed data in Phase II study cohorts.

3D spinal cord
Scholar Rock announced 12-month results from its Phase II TOPAZ study of apitegromab • Source: Shutterstock

More from R&D

More from Scrip